Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CAMELLIA Adds To Belviq’s CV Confidence But ‘Caution’ Still Needed

Executive Summary

Full results from a large cardiovascular outcomes study with Belviq show the Eisai/Arena obesity drug was not associated with higher such risk versus placebo, but neither did it show benefits in reducing major CV events, leaving uncertainty over its increased uptake amid lingering issues around diabetes and valvulopathy risks.


Related Content

Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts